Pharma Partnerships Leverage a history of Roche and Novo Nordisk integrations to co-develop digital diabetes management offerings with pharmaceutical partners, emphasizing connected device interoperability, data sharing, and real‑world evidence to support adherence and outcomes.

Population Health Position mySugr as a scalable diabetes care platform for payers and health systems, delivering coaching, therapy management, automated data tracking, and population analytics to reduce costs and improve outcomes.

Device Ecosystem Accelerate device ecosystem expansion by onboarding additional insulin pen makers and CGM providers, enabling broader data capture, seamless device integration, and richer patient insights alongside Novo Nordisk integration.

Enterprise Readiness Highlight robust security, regulatory compliance and scalable DevOps capabilities to win larger healthcare customers, with clear ROI on engagement, adherence, and care coordination.

Market Expansion Explore expansion into broader European markets and the U.S. by aligning with regulatory requirements, payer contracting, and enterprise partnerships, using existing Roche/Novo Nordisk relationships as credibility anchors.